BMT CTN Protocol 1601 - ECOG-ACRIN EA4151 MCL

A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission.

Below are protocol-related documents, which may be periodically updated.

             Protocol Chair: Timothy Fenske, MD

             BMT CTN Chair: Matthew Lunning, MD        

             Protocol Coordinator: Haleigh Wetzel

             BMT CTN Protocol Coordinator: Amy Foley


For the ECOG-ACRIN EA4151/BMT CTN 1601 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: For questions about the study and how to participate, contact the ECOG-ACRIN protocol coordinator, Haleigh Wetzel, at or 857-504-2900, or the CTSU Help Desk at or 1 888 823-5923.